Respiratory Medicine and Research最新文献

{"title":"BAP-1 in the diagnosis of malignant pleural mesothelioma","authors":"Irene Sansano ,&nbsp;Ana Vázquez ,&nbsp;Oscar Persiva ,&nbsp;Marc Simó ,&nbsp;Leire Sánchez ,&nbsp;Pilar Montoya ,&nbsp;Carme Dinarès ,&nbsp;Carmen Alemán","doi":"10.1016/j.resmer.2025.101231","DOIUrl":"10.1016/j.resmer.2025.101231","url":null,"abstract":"<div><h3>Background</h3><div>The diagnosis of malignant pleural mesothelioma (MPM) can be challenging for clinicians and pathologists.</div></div><div><h3>Patients and methods</h3><div>This study included all patients diagnosed with pleural mesothelioma between October 2013 and April 2024. Clinical data, history of asbestos exposure, pleural fluid analysis, chest-X-ray, thoracic computed tomography and positron emission tomography findings, video-assisted thoracic surgery report, pleural fluid cytology and pleural biopsy results were included. Loss of BRCA1-associated protein 1 (BAP1) nuclear staining was examined in cytologies and biopsies.</div></div><div><h3>Results</h3><div>Forty-one patients were diagnosed with pleural mesothelioma, 35 epithelioid, 5 sarcomatoid and 1 biphasic. The diagnosis was established after the first sample in 30 patients, while a second one was necessary in 11 patients. BAP1 loss in pleural cytology and histology was not always consistent. Sixteen patients showed loss of BAP1 expression in cytology. Among these, 10 patients also presented BAP1 loss in pleural histology, whereas 5 patients with BAP1 loss in histology did not show BAP1 loss in cytology. Additionally, two patients initially diagnosed with idiopathic pleural effusion and 3 patients diagnosed with benign pleural effusion due to asbestos showed BAP1 loss and were later diagnosed with MPM during follow-up.</div></div><div><h3>Conclusion</h3><div>MPM remains difficult to diagnose. Performing BAP1 immunohistochemistry in patients with an undiagnosed pleural effusion or a history of asbestos exposure can aid in identifying those with mesothelioma.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101231"},"PeriodicalIF":1.8,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146167427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic myelomonocytic leukaemia occurring in patients with pulmonary Langerhans cell histiocytosis: A common progenitor?","authors":"Pierre Thoré,&nbsp;Sérine Chaibi,&nbsp;Matthieu Duchmann,&nbsp;Raphaël Itzykson,&nbsp;Amira Benattia,&nbsp;Abdellatif Tazi","doi":"10.1016/j.resmer.2025.101221","DOIUrl":"10.1016/j.resmer.2025.101221","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101221"},"PeriodicalIF":1.8,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145565535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to the comment of Yu Tian et al. on “Increasing sleep apnoea burden in the elderly in Finland from 1996 to 2018: A national registry study”","authors":"Hannele Hasala,&nbsp;Tiina Mattila,&nbsp;Hanna-Riikka Kreivi,&nbsp;Heidi Avellan-Hietanen,&nbsp;Tuula Vasankari,&nbsp;Fredrik Herse,&nbsp;Riikka-Leena Leskelä,&nbsp;Sanna Toppila-Salmi,&nbsp;Marina Erhola,&nbsp;Tuija Jääskeläinen,&nbsp;Tari Haahtela","doi":"10.1016/j.resmer.2025.101226","DOIUrl":"10.1016/j.resmer.2025.101226","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101226"},"PeriodicalIF":1.8,"publicationDate":"2025-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gas embolism during pleural lavage for empyema : potential risk factors from two clinical cases","authors":"Martin Boussuges ,&nbsp;Mathilde Cadic ,&nbsp;Aurélie Kienlen ,&nbsp;Pierre-Jean Marianne Dit Cassou ,&nbsp;Thomas Masseguin ,&nbsp;Cyril D’Andrea","doi":"10.1016/j.resmer.2025.101225","DOIUrl":"10.1016/j.resmer.2025.101225","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101225"},"PeriodicalIF":1.8,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145662405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moving towards COPD control: Lessons, challenges, and the role of CONDOR, a new French respiratory research network","authors":"Bruno Ribeiro-Baptista ,&nbsp;Pierre-Olivier Girodet ,&nbsp;Olivier Le Rouzic ,&nbsp;Maéva Zysman ,&nbsp;Nicolas Roche ,&nbsp;Lucile Regard","doi":"10.1016/j.resmer.2025.101224","DOIUrl":"10.1016/j.resmer.2025.101224","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101224"},"PeriodicalIF":1.8,"publicationDate":"2025-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Organising pneumonia following amivantamab treatment: a case report","authors":"Gaspard Naulleau ,&nbsp;Lise Matton ,&nbsp;Ioana Hutuca ,&nbsp;Xavier Fremand ,&nbsp;Florence Jeny ,&nbsp;Boris Duchemann","doi":"10.1016/j.resmer.2025.101227","DOIUrl":"10.1016/j.resmer.2025.101227","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"89 ","pages":"Article 101227"},"PeriodicalIF":1.8,"publicationDate":"2025-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145624752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evolving paradigms in pulmonary hypertension: Highlights of the 6th French Pulmonary Hypertension Network Meeting","authors":"Athénaïs Boucly ,&nbsp;Antoine Beauvais ,&nbsp;Thomas Lacoste-Palasset ,&nbsp;Mitja Jevnikar ,&nbsp;Marianne Riou ,&nbsp;Sabina Solinas ,&nbsp;Fabrice Antigny ,&nbsp;Fabrice Bauer ,&nbsp;Laurent Bertoletti ,&nbsp;Damien Bonnet ,&nbsp;Ari Chaouat ,&nbsp;Vincent Cottin ,&nbsp;Michele D’Alto ,&nbsp;Marion Delcroix ,&nbsp;Mélanie Gallant Dewavrin ,&nbsp;Christophe Guignabert ,&nbsp;Sébastien Hascoet ,&nbsp;David G Kiely ,&nbsp;Xavier Jaïs ,&nbsp;Etienne-Marie Jutant ,&nbsp;David Montani","doi":"10.1016/j.resmer.2025.101215","DOIUrl":"10.1016/j.resmer.2025.101215","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101215"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145415517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and incidence of adult bronchiectasis in Hong Kong from 2008–2023: A population-based cohort study","authors":"ZhiLing Yuan ,&nbsp;Philip CM Au ,&nbsp;Ching Lung Cheung ,&nbsp;James Chung Man Ho ,&nbsp;Wang Chun Kwok","doi":"10.1016/j.resmer.2025.101220","DOIUrl":"10.1016/j.resmer.2025.101220","url":null,"abstract":"<div><div>While the incidence and prevalence of bronchiectasis was reported to be increasing in different parts of the world, the epidemiological data on adult bronchiectasis in Hong Kong is lacking. We aim to investigate the incidence and prevalence of adult bronchiectasis patients in Hong Kong, and to assess the changes in trends over time.</div><div>The study population was identified through the Clinical Data Analysis and Reporting System (CDARS) of Hospital Authority, Hong Kong. Patients aged 20 or above with the diagnostic code of bronchiectasis managed in all public hospitals and clinics in Hospital Authority, Hong Kong from 2008 to 2023 were retrospectively recruited. Joinpoint regression was employed to analyze trends in prevalence and incidence, estimating the average annual percent change (AAPC).</div><div>The overall prevalence of adult bronchiectasis in Hong Kong has been steadily rising from 2008 to 2023. The prevalence increased from 176.30 per 100,000 population (95 % CI 172.83 to 179.77) in 2008 to 238.09 per 100,000 population (95 % CI 234.34 to 241.85) in 2023, with AAPC 2.20 (95 % CI 1.82 to 2.22). The overall bronchiectasis incidence rate remained relatively stable from 18.48 per 100,000 population to 19.15 per 100,000 population from 2008 to 2023. In 2019, the incidence of bronchiectasis peaked at 25.38 per 100,000 population (95 % CI 21.64 to 29.11).</div><div>The prevalence of adult bronchiectasis has been increasing from year 2008 to 2023 in Hong Kong, with a largely stable incidence. The results concur with other epidemiological studies in other countries.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101220"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145519209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-acting muscarinic antagonist versus leukotriene receptor antagonist as additional treatment in uncontrolled asthma patients used inhaled corticosteroids and long-acting β2 adrenergic agonist: a randomized phase 2 screening trial","authors":"Fumiya Nihashi ,&nbsp;Kazuki Furuhashi ,&nbsp;Mitsuru Niwa ,&nbsp;Hirotsugu Hasegawa ,&nbsp;Yusuke Kaida ,&nbsp;Mikio Toyoshima ,&nbsp;Naoki Koshimizu ,&nbsp;Toshihiro Shirai ,&nbsp;Masato Fujii ,&nbsp;Kazutaka Mori ,&nbsp;Masaki Ikeda ,&nbsp;Yusuke Inoue ,&nbsp;Hideki Yasui ,&nbsp;Hironao Hozumi ,&nbsp;Yuzo Suzuki ,&nbsp;Masato Karayama ,&nbsp;Noriyuki Enomoto ,&nbsp;Tomoyuki Fujisawa ,&nbsp;Naoki Inui ,&nbsp;Takafumi Suda","doi":"10.1016/j.resmer.2025.101191","DOIUrl":"10.1016/j.resmer.2025.101191","url":null,"abstract":"<div><div>Bronchial asthma is a common disease treated primarily with inhaled corticosteroids (ICS) and long-acting beta-2 agonists (LABA), yet optimal add-on therapy with long-acting muscarinic antagonists (LAMA) or leukotriene receptor antagonists (LTRA) remains unclear. This multicenter, randomized, open-label phase 2 screening trial compared the efficacy of adding tiotropium (LAMA) versus montelukast (LTRA) to ICS/LABA therapy in adult patients with poorly controlled asthma. Patients were randomly assigned to receive either tiotropium or montelukast for 12 weeks. Primary outcome was the change in forced expiratory volume in 1 second (FEV₁), secondary outcomes included changes in asthma control questionnaire (ACQ-5), asthma control test (ACT) scores, and peak expiratory flow (PEF). Ninety-four patients were analyzed. Over 12 weeks, the tiotropium group showed significant improvements in FEV₁ and PEF, while the montelukast group showed no improvement in respiratory function. Both groups, however, showed significant improvements in ACQ-5 and ACT. The primary endpoint, change in FEV₁ improved similarly in both groups (tiotropium 2.03 ± 0.74 to 2.10 ± 0.72 L vs montelukast 2.08 ± 0.69 to 2.13 ± 0.67 L; <em>p</em> = 0.736), while the tiotropium group exhibited a significantly greater improvement in PEF (tiotropium 5.41 ± 1.85 to 5.92 ± 1.93 L/s vs montelukast 5.58 ± 1.84 to 5.65 ± 1.82 L/s; <em>p</em> = 0.025). Subgroup analysis of patients with allergic rhinitis revealed the ACQ-5 score was significantly improved in the montelukast group (tiotropium 0.94 ± 0.64 to 0.68 ± 0.76 L/s vs montelukast 1.26 ± 1.15 to 0.53 ± 0.86 L/s; <em>p</em> = 0.002). Adding tiotropium to ICS/LABA therapy improves respiratory function, whereas adding montelukast enhances symptom control, particularly in patients with allergic rhinitis. These findings underscore the importance of personalized treatment approaches in asthma management by demonstrating that both tiotropium and montelukast confer distinct benefits according to patient characteristics, while also addressing a significant gap in the literature regarding optimal adjunctive therapies for adult asthma, given the scarcity of studies directly comparing these add-on strategies. Further research is needed to establish definitive guidelines for optimal add-on therapies in asthma.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101191"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of the mini nutritional assessment short-form and SpO₂/FiO₂ ratio at admission for in-hospital mortality in patients with interstitial lung disease","authors":"Mayuko Ishiwari,&nbsp;Yuta Kono,&nbsp;Yuki Togashi,&nbsp;Kenichi Kobayashi,&nbsp;Ryota Kikuchi,&nbsp;Mariko Kogami,&nbsp;Shinji Abe","doi":"10.1016/j.resmer.2025.101222","DOIUrl":"10.1016/j.resmer.2025.101222","url":null,"abstract":"<div><h3>Background</h3><div>Hospitalization of patients with interstitial lung disease (ILD) is a poor prognostic factor. Simple and rapid biomarkers at the time of admission of hospitalized ILD patients are needed. The aim of this study was to investigate prognostic biomarkers in hospitalized patients with ILD.</div></div><div><h3>Methods</h3><div>A total of 95 consecutive hospitalized patients aged ≥ 65 years with ILD were retrospectively enrolled from April 2022 to December 2024 at Tokyo Medical University Hospital, Tokyo, Japan. Clinical and laboratory parameters at admission were retrospectively collected, and risk factors for in-hospital mortality were evaluated.</div></div><div><h3>Results</h3><div>The median age was 77 years (IQR: 72–83), and 62 patients (65.0 %) were male. Sixty-nine patients (73.0 %) were ex-smokers. Thirty patients (31.5 %) died during hospitalization, with a median time to death of 19 days (IQR: 10–28). Univariable analysis revealed that a low SpO₂/FiO₂ (S/F) ratio (&lt;419) (<em>p</em> = 0.0003), high neutrophil-to-lymphocyte ratio (NLR) (≥6.5) (<em>p</em> = 0.0003), Glasgow Prognostic Score (GPS) 2 (<em>p</em> = 0.0383), and low Mini Nutritional Assessment Short-Form (MNA-SF) score (&lt;11) (<em>p</em> = 0.0007) were significantly associated with in-hospital mortality of hospitalized patients with ILD. In the multivariable analysis, S/F ratio (<em>p</em> = 0.0116) and low MNA-SF score (<em>p</em> = 0.0289) had a significant effect on the prognosis of hospitalized patients with ILD.</div></div><div><h3>Conclusions</h3><div>Nutritional risk assessed by the MNA-SF, together with oxygenation status measured by the S/F ratio, could serve as valuable and readily available prognostic biomarkers for hospitalized patients with ILD.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101222"},"PeriodicalIF":1.8,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145514564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}